$20m-$39.9m

U-M commits $20m to four spinouts
University of Michigan has committed an initial $2.75m in combined funding to MemryX, Ripple Science, GreenMark Biomedical, and Give and Take, and could invest as much as $20m altogether.
Neuspera restimulates $26m series B
Neuspera Medical has secured a $12m extension to bring its series B round to the targeted $26m close, with all investors from the first tranche returning.
KenSci foretells $22m series B
The UW-founded healthcare forecasting software developer has collected $30.5m in all from backers including OUP and a unit of compliance firm UL.
Sustainable Bioproducts sucks in $33m
Danone Manifesto Ventures and ADM Ventures both took part in a series A round for the Montana State University-backed Nasa spinout, which is developing edible proteins.
Knotch captures $20m series B
Backed by Stanford-StartX Fund, marketing intelligence platform Knotch has now secured at least $31.5m in total funding and will now pursue technology upgrades and and internal expansion.
Featurespace authenticates $32.9m funding round
IP Group put up $5.4m for Cambridge fraud detection spinout Featurespace’s latest round to bring the company’s overall funding haul to $70.9m.
Wren Therapeutics settles on $23.3m series A
Wren Therapeutics is commercialising Cambridge and Lund research into therapies for protein misfolding diseases, which include Alzheimer's and motor neurone disease.
ETH Zurich ignites 27 spinouts in 2018
ETH Zurich spinouts lifted their total funding haul to $173.3m from $123.1m in 2017.

Other News

Exscientia sends for $26m
Celgene and Evotec have put capital into Exscientia as the Dundee-founded automated drug discovery services provider added Roche to its roster of development partners.
Baraja jives for $32m series A
Lidar technology developer Baraja has lured the support of Csiro's Innovation Fund as it pursues additional business for its autonomous vehicle perception system in the US and Asia.
Osler to obtain $38m
Based on Oxford and Sao Paulo State University research, Osler Diagnostics is reportedly set to secure $38m to add to the $2.6m it raised in 2016.
Morphogen-IX clears path to series B round
Pulmonary arterial hypertension therapy business Morphogen-IX has been backed by Cambridge Enterprise and Cambridge Innovation Capital in a $23.3m round.
Mission Bio identifies $30m series B
Agilent and Lam Research participated in a $30m series B for UCSF's DNA analysis spinout Mission Bio, whose existing shareholders include Stanford-StartX Fund.
Axelspace explores $23m series B round
UTokyo Innovation Platform has backed a $22.8m investment round for Axelspace that will fund the launch of the Tokyo spinout's latest satellite.

Editor's Picks

Tel Aviv partners with Tata
Tel Aviv University announces $20m commercialisation fund with Tata Industries.
UK graphene research nets $35m backing
Cell Medica raises $26.5m
Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, are joined by The Cancer Prevention and Research Institute of Texas and the Wellcome Trust supporting Cell Medica's growth.
Revolymer sticks to AIM in IPO
Revolymer, which makes chewing gum that is easier to remove from streets and pavements, was backed by the Setsquared Partnership, a joint venture capital initiative between Bath, Bristol, Exeter, Southampton and Surrey.
test reg

Login